TABLE 1.
Demographics characteristics of participants treated with tunlametinib.
| Characteristics | 0.5 mg (n = 3) | 1 mg (n = 3) | 2 mg (n = 3) | 3 mg (n = 3) | 4 mg (n = 3) | 6 mg (n = 3) | 9 mg (n = 3) | 12 mg (n = 14)* | 15 mg (n = 3) | 18 mg (n = 3) | Total (n = 41) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 55.0 (36–63) | 54.0 (43–62) | 46.0 (43–52) | 50.0 (39–55) | 62.0 (45–69) | 58.0 (44–68) | 58.0 (56–59) | 56.5 (41–67) | 57.0 (34–58) | 59.0 (56–63) | 56.0 (34–69) |
| Sex-no. (%) | |||||||||||
| Female | 2 (66.7%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) | 2 (66.7%) | 1 (33.3%) | 1 (33.3%) | 7 (500%) | 3 (100%) | 1 (33.3%) | 20 (48.8%) |
| Male | 1 (33.3%) | 2 (66.7%) | 2 (66.7%) | 2 (66.7%) | 1 (33.3%) | 2 (66.7%) | 2 (66.7%) | 7 (50.0%) | 0 | 2 (66.7%) | 21 (51.2%) |
| Height (cm) | 160.00 (154.0–172.0) | 166.00 (148.0–167.0) | 165.00 (160.0–172.0) | 173.00 (154.0–180.0) | 161.00 (150.0–170.0) | 167.00 (159.0–175.0) | 165.00 (158.0–171.0) | 164.00 (158.0–175.0) | 160.00 (153.0–163.0) | 158.00 (157.0–159.0) | 163.00 (148.0–180.0) |
| Weight (kg) | 56.00 (48.0–72.0) | 69.00 (62.0–85.0) | 72.00 (62.0–84.0) | 67.00 (55.0–75.0) | 61.00 (60.0–78.0) | 68.00 (67.4–87.0) | 56.00 (49.0–88.0) | 65.75 (46.0–98.0) | 64.00 (54.0–75.0) | 66.30 (59.0–71.5) | 67.00 (46.0–98.0) |
| BMI (kg/m2) | 21.88 (20.24–24.34) | 28.31 (25.04–30.48) | 24.34 (22.77–32.81) | 23.15 (22.39–23.19) | 26.67 (23.53–26.99) | 26.90 (24.17–28.41) | 20.57 (19.63–30.09) | 23.56 (18.43–36.00) | 25.00 (20.32–32.04) | 26.90 (23.34–28.64) | 24.17 (18.43–36.00) |
Data was presented as median and range (min, max) unless otherwise specific indicated.
BMI: body mass index.
*12 mg cohort include 3 patients in dose-escalation phase and 11 patients in dose-expansion phase.